Rigidity of large arteries and cardiovascular risk. Epidemiological considerations and genetic determinants;Rigidite des gros troncs arteriels et risque cardiovasculaire. Aspects epidemiologiques et determinants genetiques

Pathologie Biologie

Volumn 47, Issue 6, 1999, Pages 614-622

  Lajemi, M ^a   Gautier, S ^a   Benetos, A ^a  

^a INSERM   (France)

Author keywords

Aorta; Arterial distensibility; Genetic polymorphism; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE;

AGING; ARTERY COMPLIANCE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ARTERY; ELASTICITY; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASCULAR DISEASE;

ALDOSTERONE; ARTERIES; CARDIOVASCULAR DISEASES; ELASTICITY; HUMANS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; VASCULAR DISEASES;

EID: 0033304141     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Pulse pressure in essential hypertension: Clinical and therapeutical implications
2. Atherosclerotic hypertension: Systolic hypertension and arterial compliance in patients with arteriosclerosis obliterans of the lower limbs
3. Pulse pressure and echocardiographic findings in essential hypertension
4. Coronary circulation in dogs with an experimental decrease in aortic compliance
5. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction
6. Measures of blood pressure and myocardial infarction in treated hypertensive patients
7. Shygmomanometric determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function
8. Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population
9. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects
10. The J-curve phenomenon and the treatment of hypertension: Is there a point beyond which pressure reduction is dangerous?
11. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly program (SHEP)
12. Medical Research Counci trial of treatment of hypertension in older adults: Principal results
13. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: Comparison between urban and rural communities in China
14. Arterial alterations with ageing and high blood pressure: A non-invasive study of carotid and femoral arteries
15. Elastic modulus of the radial artery wall material is not increased in patients with essential hypertension
16. Acute changes in forearm haemodynamics produced by cigarette smoking in healthy normotensive non-smokers are not influenced by propranolol or pindolol
17. Ambulatory blood pressure measurement, smoking and abnormalities of glucose and lipid metabolism in essential hypertension
18. Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
19. Large conduits arteries in hypertension: Role of the renin-angiotensin system
20. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats
21. Comparison of oral MK 421 and propranolol and their effects on arterial and venous vessels of the forearm
22. Long lasting arterial effects of the ACE inhibitor ramipril
23. Vascular effect of intravenous infusion of the ACE inhibitor perindoprilat
24. Dose-related changes in the mechanical properties of the carotid artery in WKY rats and SHR following relaxation of arterial smooth muscle
25. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats
26. Influence of Angiotensin II on aortic structures following converting enzyme inhibition in spontaneously hypertensive rats
27. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin
28. Aldosterone inhibits nitric oxyde synthesis in rat vascular smooth muscle cells induced by interleukin-lb
29. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells
30. Production of aldosterone in isolated rat blood vessels
31. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor
32. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system
33. Biological determinants of aldosterone-induced cardiac fibrosis in rats
34. A lack of genetic linkage of renin gene restriction fragment length polymorphisms with human hypertension
35. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction
36. Molecular basis of human hypertension: Role of angiotensinogen
37. Angiotensin II Type 1 receptor gene polymorphisms in human essential hypertension
38. Associations between human aldosterone synthase (CYP1 1B2) gene polymorphisms and left ventricular size, mass, and function
39. The angiotensin I converting enzyme gene and predisposition to high pressure
40. Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension
41. Genetic determination of plasma aldosterone levels in essential hypertension
42. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction
43. Synergestic effects of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphism on the risk of myocardial infarction
44. Association between a deletion polymorphism of the angiotensin converting enzyme gene and left ventricular hypertrophy
45. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy
46. Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension
47. Left ventricular hypertrophy, blood pressure and ACE genotype in untreated hypertension
48. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in general population. The Vobarno study
49. Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: The atherosclerosis risk in communities and the NHLBI family heart studies
50. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis
51. Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease
52. The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction
53. Influence of angiotensin II Type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients
54. Influence of angiotensin converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients
55. Angiotensin II AT1 receptor gene polymorphism influences the efficacy of chronic angiotensin converting enzyme inhibition on blood pressure and arterial stiffness in hypertensives
56. Antihypertensive actions of propranolol. Specific anti-renin responses in high and normal renin forms of essential, renal, neurovascular and malignant hypertension
57. Renin dependency of blood pressure in isolated systolic hypertension
58. Antihypertensive therapy with MK-421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade
59. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients